GSK nears end of OTC bidding process

GlaxoSmithKline ($GSK) is weighing final offers for the portfolio of over-the-counter products it has put on the block, sources tell Reuters. The two front-runners in the second round of bidding are Bain Capital and a partnership between Blackstone and Prestige Brands, the sources said. Report

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.